Managed Account Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Managed Account Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$6.63M	Sell	158,250 -9,728	-6%	-$377K	0.01%	1285
2015 Q1	$5.47M	Sell	167,978 -47,022	-22%	-$1.62M	﹤0.01%	1390
2014 Q4	$6.83M	Buy	215,000 +35,326	+20%	+$1M	0.01%	1242
2014 Q3	$4.45M	Sell	179,674 -38,480	-18%	-$900K	0.01%	1439
2014 Q2	$4.93M	Sell	218,154 -8,100	-4%	-$169K	0.01%	1368
2014 Q1	$5.5M	Sell	226,254 -75,053	-25%	-$1.9M	0.01%	1266
2013 Q4	$7.53M	Buy	301,307 +44,838	+17%	+$1.06M	0.01%	1102
2013 Q3	$7.04M	Buy	256,469 +52,094	+25%	+$1.09M	0.01%	1082
2013 Q2	$3.71M	Buy	+204,375	New	+$2.82M	0.01%	1338

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Managed Account Advisors's ACAD Position: Q2 2015 in Review

Managed Account Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 5.8% in Q2 2015, selling an estimated $377K and leaving 158,250 shares worth $6.63M. The position accounts for 0.01% of the portfolio, ranked #1285.

Managed Account Advisors first reported a position in ACAD in Q2 2013 and has held it in 9 quarters since. The position peaked at $7.53M in Q4 2013. 188 funds tracked by Wall St. Rank hold ACAD as of Q2 2015.

Managed Account Advisors held 158,250 shares of Acadia Pharmaceuticals worth $6.63M as of Q2 2015.
Managed Account Advisors sold 9,728 Acadia Pharmaceuticals shares in Q2 2015, an estimated $377K.
Acadia Pharmaceuticals made up 0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1285 holding.
Managed Account Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's Acadia Pharmaceuticals position peaked at $7.53M in Q4 2013.
188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.